Increased Levels of Plasma Galectin-9 in Patients with Influenza Virus Infection
-
- Katoh Shigeki
- Department of Respiratory Medicine, Kawasaki Medical School
-
- Ikeda Masaki
- Department of Respiratory Medicine, Kawasaki Medical School
-
- Shimizu Hiroki
- Department of Respiratory Medicine, Kawasaki Medical School
-
- Mouri Keiji
- Department of Respiratory Medicine, Kawasaki Medical School
-
- Obase Yasushi
- Department of Respiratory Medicine, Kawasaki Medical School
-
- Kobashi Yoshihiro
- Department of Respiratory Medicine, Kawasaki Medical School
-
- Fukushima Kiyoyasu
- Division of Respiratory Disease, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital
-
- Hirashima Mistuomi
- Department of Immunology and Immunopathology, Faculty of Medicine, Kagawa University
-
- Oka Mikio
- Department of Respiratory Medicine, Kawasaki Medical School
この論文をさがす
抄録
Galectin-9 (Gal-9) is a β-galactoside-binding protein involved in various biologic processes, including cell aggregation, adhesion, chemoattraction, and apoptosis. Little is known, however, about the regulation mechanisms of Gal-9 production. Recent studies reported high plasma Gal-9 levels in humans infected with human immunodeficiency virus-1 and dengue virus. Viral respiratory infections such as influenza are common human illnesses. A synthetic double-stranded RNA, polyinosinic-polycytidylic acid (PolyIC), mimics the effects of viruses in various cell types and induces the expression of Gal-9 in endothelial cells. To examine the potential link between viral infection and Gal-9 expression, we measured plasma Gal-9 concentrations in patients with influenza. Subjects were 43 patients with influenza virus infection, 20 with pneumococcal pneumonia, and 20 healthy adults. Gal-9 concentrations in the plasma and in culture supernatants of human airway epithelial cells were measured using an enzyme-linked immunosorbent assay. Plasma Gal-9 concentrations were higher in patients with influenza infection than in patients with pneumococcal pneumonia and healthy subjects (p < 0.05). Patients with influenza were effectively differentiated from those with pneumococcal pneumonia or healthy subjects, based on the plasma levels of Gal-9 (p < 0.0001). Furthermore, using a human airway epithelial cell line, we showed that the presence of PolyIC but not lipopolysaccharides increased the Gal-9 concentration in the culture medium (p < 0.05), suggesting that PolyIC enhanced Gal-9 production. These findings support our proposal that Gal-9 production is induced by influenza virus infection in humans. In conclusion, plasma Gal-9 could be a new biomarker for patients with influenza infection.
収録刊行物
-
- The Tohoku Journal of Experimental Medicine
-
The Tohoku Journal of Experimental Medicine 232 (4), 263-267, 2014
東北ジャーナル刊行会
